Upgrade to SI Premium - Free Trial

CEL-SCI Corp (CVM)

1.47 -0.01 (0.68%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/18/26 *Est.)

Latest Headlines

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology September 15, 2026 8:37 AM - BizWire Form S-8 CEL SCI CORP September 3, 2026 4:47 PM - SEC Filing Form 4 CEL SCI CORP For: Aug 25 Filed by: KERSTEN GEERT R August 26, 2026 8:33 AM - SEC Filing Form 4 CEL SCI CORP For: Aug 14 Filed by: Watson Robert Eugene August 17, 2026 9:43 AM - SEC Filing Form 4 CEL SCI CORP For: Aug 14 Filed by: BAILLAVOINE BRUNO JEAN-MARIE August 17, 2026 9:37 AM - SEC Filing Form 4 CEL SCI CORP For: Aug 14 Filed by: CIPRIANO JOHN August 17, 2026 9:33 AM - SEC Filing Form 4 CEL SCI CORP For: Aug 14 Filed by: TALOR EYAL August 17, 2026 9:27 AM - SEC Filing Form 4 CEL SCI CORP For: Aug 14 Filed by: PRICHEP PATRICIA B August 17, 2026 9:23 AM - SEC Filing Form 4 CEL SCI CORP For: Aug 14 Filed by: KERSTEN GEERT R August 17, 2026 9:19 AM - SEC Filing Form 8-K CEL SCI CORP For: Aug 14 August 17, 2026 9:05 AM - SEC Filing CEL-SCI Reports Fiscal Third Quarter 2026 Results August 17, 2026 8:30 AM - BizWire Form 10-Q CEL SCI CORP For: Jun 30 August 14, 2026 4:25 PM - SEC Filing CEL-SCI publishes Multikine study in Oral Oncology journal August 4, 2026 8:04 AM - StreetInsider CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study August 4, 2026 8:00 AM - BizWire CEL-SCI Multikine Phase 3 data accepted by Oral Oncology journal July 30, 2026 8:31 AM - StreetInsider Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients July 30, 2026 8:31 AM - BizWire CEL-SCI launches phase 3 confirmatory study for head and neck cancer drug July 13, 2026 8:01 AM - StreetInsider CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer July 13, 2026 8:00 AM - BizWire Form ARS CEL SCI CORP For: Sep 30 July 2, 2026 5:08 PM - SEC Filing Form DEF 14A CEL SCI CORP For: Jun 23 July 2, 2026 5:02 PM - SEC Filing Form 4 CEL SCI CORP For: Jun 30 Filed by: TALOR EYAL July 1, 2026 8:41 AM - SEC Filing Form 4 CEL SCI CORP For: Jun 30 Filed by: PRICHEP PATRICIA B July 1, 2026 8:38 AM - SEC Filing Form 4 CEL SCI CORP For: Jun 30 Filed by: KERSTEN GEERT R July 1, 2026 8:33 AM - SEC Filing CEL-SCI signs distribution deal with Saudi Amarox for cancer drug June 24, 2026 8:00 AM - StreetInsider CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care June 24, 2026 8:00 AM - BizWire Full Article List